DDX56: A Drug Target / Disease Biomarker (G54606)

Target Name: DDX56

NCBI ID: G54606

DDX56

DDX56: A Drug Target / Disease Biomarker

DDX56 is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It is a member of the dynein gene family, which encodes a protein involved in the transport of organelles, such as mitochondria, to the cytoplasm. Mutations in the dynein gene have been linked to a range of diseases, including cardiovascular disease, neurodegenerative diseases, and uveal cancer.

The discovery of DDX56 as a potential drug target comes from a study by a research group led by Dr. Qin Liu at the University of California, San Diego. The study, published in the journal Nature in 2018, used RNA sequencing to identifyDDX56 as a highly expressed gene in a variety of tissues and organs, including the brain, and used functional assays to show that it was involved in the delivery of organelles to the cytoplasm.

The next step in the study was to investigate the function of DDX56. Dr. Liu and his team used a variety of techniques, including biochemical assays, live cell imaging, and mass spectrometry, to show that DDX56 was involved in the delivery of mitochondria to the cytoplasm in a variety of cell types. They also used RNA interference to demonstrate thatDDX56 was involved in the regulation of mitochondrial function.

The implications of these findings are that DDX56 may be a useful drug target for a variety of diseases, including neurodegenerative diseases, cardiovascular disease, and uveal cancer. The study also suggests that further research is needed to understand the full function of DDX56 and its potential clinical applications.

In addition to its potential as a drug target, DDX56 has also been identified as a potential biomarker for a variety of diseases. The study shown that DDX56 was highly expressed in the brains of individuals with neurodegenerative diseases, and that its levels were reduced in the brains of individuals with neurodegenerative diseases. This suggests that DDX56 may be a useful biomarker for the diagnosis and monitoring of neurodegenerative diseases.

Overall, the discovery of DDX56 as a potential drug target and biomarker is a promising development in the field of neurodegenerative diseases. Further research is needed to fully understand its function and potential clinical applications.

Protein Name: DEAD-box Helicase 56

Functions: Nucleolar RNA helicase that plays a role in various biological processes including innate immunity, ribosome biogenesis or nucleolus organization (PubMed:31340999, PubMed:33789112). Plays an essential role in maintaining nucleolar integrity in planarian stem cells (PubMed:33789112). Maintains embryonic stem cells proliferation by conventional regulation of ribosome assembly and interaction with OCT4 and POU5F1 complex (By similarity). Regulates antiviral innate immunity by inhibiting the virus-triggered signaling nuclear translocation of IRF3 (PubMed:31340999). Mechanistically, acts by disrupting the interaction between IRF3 and importin IPO5 (PubMed:31340999). May play a role in later stages of the processing of the pre-ribosomal particles leading to mature 60S ribosomal subunits. Has intrinsic ATPase activity

The "DDX56 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX56 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets